These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30139570)

  • 1. How to mitigate the risk of inducing transfusion-associated adverse reactions.
    Garraud O; Cognasse F; Laradi S; Hamzeh-Cognasse H; Peyrard T; Tissot JD; Fontana S
    Transfus Clin Biol; 2018 Nov; 25(4):262-268. PubMed ID: 30139570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The revision of the European blood directives: A major challenge for transfusion medicine.
    Folléa G; Aranko K;
    Transfus Clin Biol; 2015 Aug; 22(3):141-7. PubMed ID: 26056039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemovigilance drives improved transfusion safety.
    Murphy MF
    Transfusion; 2021 Apr; 61(4):1333-1335. PubMed ID: 33831223
    [No Abstract]   [Full Text] [Related]  

  • 4. How to reposition the benefice-risk balance to safely transfuse patients in non-vital situations?
    Garraud O
    Transfus Clin Biol; 2019 Sep; 26(3):171-173. PubMed ID: 31255510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The best blood product and its best use for each patient: An evolving role for hemovigilance?
    Tiberghien P
    Transfus Clin Biol; 2019 Sep; 26(3):188-191. PubMed ID: 31178340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Why is it necessary to review the December 15th 2003 circular relative to the transfusion act?].
    Lassale B; Besse-Moreau M; Aullen JP
    Transfus Clin Biol; 2014 Nov; 21(4-5):223-6. PubMed ID: 25267206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion-associated hazards: A revisit of their presentation.
    Garraud O; Sut C; Haddad A; Tariket S; Aloui C; Laradi S; Hamzeh-Cognasse H; Bourlet T; Zeni F; Aubron C; Ozier Y; Laperche S; Peyrard T; Buffet P; Guyotat D; Tavernier E; Cognasse F; Pozzetto B; Andreu G
    Transfus Clin Biol; 2018 May; 25(2):118-135. PubMed ID: 29625790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How clinicians can minimize transfusion-related adverse events?
    Aubron C; Aries P; Le Niger C; Sparrow RL; Ozier Y
    Transfus Clin Biol; 2018 Nov; 25(4):257-261. PubMed ID: 30197000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct costs of transfusion reactions - an expert judgement approach.
    Janssen MP; van Tilborgh AJW; de Vooght KMK; Bokhorst AG; Wiersum-Osselton JC
    Vox Sang; 2018 Feb; 113(2):143-151. PubMed ID: 29124766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood donor hemovigilance: impact for donor and recipient safety].
    Hauser L; Beyloune A; Simonet M; Bierling P
    Transfus Clin Biol; 2013 May; 20(2):99-103. PubMed ID: 23587614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018.
    Kracalik I; Mowla S; Basavaraju SV; Sapiano MRP
    Transfusion; 2021 May; 61(5):1424-1434. PubMed ID: 33880771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion and hemovigilance in pediatrics.
    Bolton-Maggs PH
    Pediatr Clin North Am; 2013 Dec; 60(6):1527-40. PubMed ID: 24237986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years of transfusion practitioners and better blood transfusion in Scotland.
    Dalrymple K; Watson D
    Nurs Manag (Harrow); 2014 Mar; 20(10):27-30. PubMed ID: 24571162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network.
    Cumming M; Osinski A; O'Hearn L; Waksmonski P; Herman M; Gordon D; Griffiths E; Knox K; McHale E; Quillen K; Rios J; Pisciotto P; Uhl L; DeMaria A; Andrzejewski C
    Transfusion; 2017 Feb; 57(2):478-483. PubMed ID: 27774608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion-related errors and associated adverse reactions and blood product wastage as reported to the National Healthcare Safety Network Hemovigilance Module, 2014-2022.
    Chavez Ortiz JL; Griffin I; Kazakova SV; Stewart PB; Kracalik I; Basavaraju SV
    Transfusion; 2024 Apr; 64(4):627-637. PubMed ID: 38476028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion practice and safety: current status and possibilities for improvement.
    Murphy MF; Stanworth SJ; Yazer M
    Vox Sang; 2011 Jan; 100(1):46-59. PubMed ID: 21175655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework for applying the precautionary principle to transfusion safety.
    Wilson K
    Transfus Med Rev; 2011 Jul; 25(3):177-83. PubMed ID: 21429704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation between hospitals in rates of reported transfusion reactions: is a high reporting rate an indicator of safer transfusion?
    Wiersum-Osselton JC; van Tilborgh-de Jong AJ; Zijlker-Jansen PY; van de Watering LM; Brand A; van der Bom JG; Schipperus MR
    Vox Sang; 2013 Feb; 104(2):127-34. PubMed ID: 22892067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemovigilance: State 2007-2013 Tunis].
    Mahjoub S; Baccouche H; Raissi A; Ben Hamed L; Ben Romdhane N
    Transfus Clin Biol; 2017 Feb; 24(1):15-22. PubMed ID: 27955922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemovigilance: an effective tool for improving transfusion practice.
    de Vries RR; Faber JC; Strengers PF;
    Vox Sang; 2011 Jan; 100(1):60-7. PubMed ID: 21175656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.